Stockwatch: What Links Actimmune And Vertex’s Event Horizon?
Executive Summary
Drug failures in Phase III and value-based pricing were two forces affecting Horizon and Vertex, respectively, last week. Biogen and Teva have shown that value, at least, is a force to be argued with.